At the time of writing, Precigen Inc [PGEN] stock is trading at $1.53, up 4.79%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PGEN shares have gain 7.75% over the last week, with a monthly amount glided 7.75%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, February 2024, Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. In a post published today on Yahoo Finance, Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024. Precigen’s company presentation will take place on Tuesday, February 13 from 3:20 PM to 3:50 PM EST.
From an analyst’s perspective:
Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on November 18, 2022, and set its price target to $7. On February 25, 2021, Stifel initiated with a Buy rating and assigned a price target of $13 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $14 on February 22, 2021. B. Riley Securities initiated its recommendation with a Buy and recommended $10 as its price target on February 18, 2021. H.C. Wainwright started tracking with a Buy rating for this stock on May 08, 2020, and assigned it a price target of $5.
For the past year, the stock price of Precigen Inc fluctuated between $0.81 and $1.88. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Precigen Inc [NASDAQ: PGEN] shares were valued at $1.53 at the most recent close of the market. An investor can expect a potential return of 292.16% based on the average PGEN price forecast.
Analyzing the PGEN fundamentals
According to Precigen Inc [NASDAQ:PGEN], the company’s sales were 6.76M for trailing twelve months, which represents an -91.75% plunge. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4333 points at the first support level, and at 1.3367 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6433, and for the 2nd resistance point, it is at 1.7567.
Precigen Inc [PGEN] reported earnings per share of -$0.08 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.08/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.08 per share as compared to estimates of -$0.1 per share, a difference of $0.02 representing a surprise of 20.00%.
Ratios To Look Out For
It is important to note that Precigen Inc [NASDAQ:PGEN] has a current ratio of 2.83. In addition, the Quick Ratio stands at 2.83 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 56.34, the price to book ratio is 2.66.
Transactions by insiders
Recent insider trading involved KIRK RANDAL J, Director, that happened on Dec 28 when 96686.0 shares were purchased. Director, KINDLER JEFFREY B completed a deal on Dec 28 to sell 96686.0 shares. Meanwhile, Director MITCHELL DEAN J bought 25000.0 shares on Sep 22.
